May 14, 2021
Company: Chiome Bioscience Inc.
Representative: Shigeru Kobayashi, President & CEO
(Code: 4583, Tokyo Stock Exchange Mothers)
Inquiries: Arihiko Bijohira, Executive Director & CFO
Termination of Collaborative Development License and Exclusive Option Agreement for
anti-Semaphorin 3A antibody
Chiome Bioscience announced that it has agreed with SemaThera Inc. to terminate the Collaborative Development License and Exclusive Option Agreement for anti-Semaphorin 3A antibody which was signed on 22 March 2018.
Both parties have been collaborating in the research of potential use of Semaphorin 3A inhibitors in diabetic macular edema under the exclusive agreement for 3 years. SemaThera will continue research and development of Sema 3A inhibitors in ophthalmology area and Chiome regains full rights to anti-Semaphorin 3A antibody for further development and licensing in all fields.
There is no impact on the financial performance in the fiscal period ending December 31, 2021.
Chiome Bioscience Inc. published this content on 14 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 May 2021 15:46:09 UTC.